CClinicalTrials.gg
RecruitingNCT06411795Updated Feb 3, 2026

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

A Phase 2 interventional study of Bupivacaine and Hydromorphone in Duodenal Neoplasm and Pancreatic Neoplasm, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Supportive care

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if rectus sheath blocks with liposomal bupivacaine provide non-inferior analgesia compared with thoracic epidural analgesia (TEA) for patients undergoing pancreatoduodenectomy.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP EPIDURAL (E): Prior to pancreatoduodenectomy, patients undergo thoracic epidural placement and receive bupivacaine and hydromorphone continuous infusion via epidural for up to 72 hours postoperatively. Patients also receive iopamidol via epidural and undergo x-ray imaging on study.

GROUP RECTUS SHEATH (RS): Prior to pancreatoduodenectomy, patients undergo ultrasound and receive bupivacaine and liposomal bupivacaine injection into the rectus sheath.

02

Conditions studied

  • Duodenal Neoplasm
  • Pancreatic Neoplasm
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients, age 18 and older, undergoing open pancreaticoduodenectomy at the University of Minnesota will be included in the study

Exclusion criteria

Exclusion Criteria:

  • Patients with contraindication to block placement (coagulopathy, local anesthetic allergy, infection)
  • Patients with chronic opioid use (at least 30 milligram morphine equivalents [MME] for 3 or more weeks leading up to surgery)
  • Patients unable to understand the quality of recovery survey intellectual barriers. This will be determined by the primary investigator/attending anesthesiologist's discretion
  • Patient refusal and those who have opted out of research
  • Pregnant patients - will be assessed through review of the medical record
04

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Group E (TEA)

    Prior to pancreatoduodenectomy, patients undergo thoracic epidural placement and receive bupivacaine and hydromorphone continuous infusion via epidural for up to 72 hours postoperatively. Patients also receive iopamidol via epidural and undergo x-ray imaging on study.

    Drug: Bupivacaine · Drug: Hydromorphone · Drug: Iopamidol · Other: Medical Chart Review · Other: Questionnaire Administration · Drug: Thoracic Epidural Analgesia · Procedure: X-Ray Imaging

  • Experimental
    Group RS (rectus sheath block)

    Prior to pancreatoduodenectomy, patients undergo ultrasound and receive bupivacaine and liposomal bupivacaine injection into the rectus sheath.

    Drug: Bupivacaine · Drug: Liposomal Bupivacaine · Other: Medical Chart Review · Other: Questionnaire Administration · Procedure: Ultrasound Imaging

Interventions

  • DrugBupivacaine

    Given via epidural and injection

    Also known as: AH 250

  • DrugHydromorphone

    Given via epidural

    Also known as: (-)-Hydromorphone, Dihydromorphinone, Hydromorphon

  • DrugIopamidol

    Given via epidural

    Also known as: Isovue, Niopam, Solutrast

  • DrugLiposomal Bupivacaine

    Given injection

    Also known as: Bupivacaine Liposome Injectable Suspension, Exparel

  • OtherMedical Chart Review

    Ancillary studies

    Also known as: Chart Review

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugThoracic Epidural Analgesia

    Undergo thoracic epidural placement

    Also known as: TEA, Thoracic Epidural

  • ProcedureUltrasound Imaging

    Undergo ultrasound

    Also known as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US

  • ProcedureX-Ray Imaging

    Undergo x-ray

    Also known as: Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

05

What researchers measure

Primary outcomes

  1. Milligram morphine equivalents (MME)

    Opioid consumption will be evaluated as a non-inferiority hypothesis using a two-sample t-test to compare the groups, with the conclusion of statistical significance being drawn from the corresponding confidence interval for the differences in mean MMEs between groups.

    Time frame: Up to 96 hours after open pancreatoduodenectomy

Secondary outcomes

  1. Pain scores

    Pain scores at rest and with movement will be assessed using a numeric rating scale pain scores where 0 is no pain and 10 is worst pain.

    Time frame: At 24, 48, 72 and 96 hours

  2. Hospital length of stay

    Average hospital length of stay

    Time frame: Up to 7 days after surgery

  3. Opioid consumption

    Average Opioid consumption (milligrams)

    Time frame: 96 hours

  4. Time to return of bowel function

    Average time to return of bowel function will be measured by first oral intake.

    Time frame: Up to 7 days after surgery

  5. Incidence of nausea, vomiting, hypotension and pruritis

    Time frame: At 24 hours, 48 hours, 72 hours and 96 hours

06

Study locations

1 of 1 sites recruiting
  • University of Minnesota/Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
    • James Flaherty · Contact · jflahert@umn.edu · 314-322-3474
    • James Flaherty · Principal investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT06411795
Lead sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Nov 10, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Feb 3, 2026

Study contacts

James Flaherty
principal investigator · Masonic Cancer Center, University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion